Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Merck & Company (MRK) Stock Price & Analysis

15,156 Followers

MRK Stock Chart & Stats

$147.76$0.81(0.55%)
At close: 4:00 PM EST
$140$150Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$145.24 - $147.99
52-Week Range
$91.49 - $156.92
Previous Close
$146.95
Volume
N/A
Average Volume (3M)
9.52M
Market Cap
$362.27B
Enterprise Value
$404.16B
Total Cash (Recent Filing)
$9.65B
Total Debt (Recent Filing)
$53.78B
Price to Earnings (P/E)
149.3
Beta
0.26
Next Earnings
Feb 02, 2027 (Est.)
EPS Estimate
1.76
Last Dividend Ex-Date
Sep 15, 2026
Dividend Yield
2.30%

Bulls Say, Bears Say

Bulls Say

Diversified Product Growth

Revenue growth is supported by multiple therapeutic and animal-health franchises rather than a single product. Continued contributions from new products, oncology and animal health broaden the earnings base and provide durable commercial momentum over the next several quarters.

Pipeline Strength

Late-stage clinical and regulatory progress strengthens Merck’s ability to replenish growth as mature products age. Positive results across oncology, vaccines and pulmonary hypertension diversify future launch opportunities and improve the durability of the portfolio.

Strong Cash Generation

Substantial operating and free cash flow gives Merck capacity to fund research, launches, capital needs, dividends and business development internally. Strong cash conversion supports financial resilience even while recent free-cash-flow growth has moderated.

Bears Say

Patent And Generic Headwinds

Upcoming loss of exclusivity and generic competition create a clearly identified pressure on revenue and earnings. The expected impact on BRIDION, Januvia and Adempas raises the execution burden for newer launches and pipeline products to offset mature-product erosion.

Profitability Deterioration

Lower operating and net margins reduce earnings quality and make reported profit less predictable, even though gross product economics remain strong. Elevated costs, charges or other below-gross-profit pressures could constrain operating leverage while Merck invests for future growth.

Higher Leverage

Higher leverage reduces balance-sheet flexibility and leaves less capacity to absorb setbacks or pursue opportunities without additional financing. The concurrent decline in equity and return on equity signals weaker recent financial resilience than in 2024–2025.

Merck & Company News

MRK FAQ

What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $91.49 and its highest was $156.92 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $362.27B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s next earnings report is estimated for Feb 02, 2027 (not yet confirmed), which is in 80 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 29, 2026. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.085 by $0.405.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a quarterly dividend of $0.85 which represents an annual dividend yield of 2.3%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.76.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,465,245,600 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.49 in its last earnings report, beating expectations of $2.085. Following the earnings report the stock price went up 3.832%.
Which hedge fund is a major shareholder of Merck & Company?
Hedge funds hold Merck & Company shares: the largest hedge-fund position in Merck & Company is 71,885,832 shares, and hedge funds increased their holdings by 12.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology